CTKB
Cytek Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CTKB
Cytek Biosciences, Inc.
A leading cell analysis solutions company
Life Science Tools and Services
--
07/23/2021
NASDAQ Stock Exchange
648
12-31
Common stock
47215 Lakeview Blvd. Fremont, California 94538
--
Cytek Biosciences, Inc., was incorporated in Delaware in December 2014. The company is a leading cell analysis solutions company, advancing the next generation of cell analysis tools with a novel technical approach to differentiate fluorescent tags on a single cell using full-spectrum fluorescence features from multiple lasers (" Full Spectrum Analysis "or" FSP "technology). The company's goal is to become a premier cell analysis company through continuous innovation, contributing to scientific progress in biomedical research and clinical applications.
Earnings Call
Q1/2025
Estimate EPS0.01
Actual EPS-0.09
Estimate Revenue42.66M
Actual Revenue41.50M
Cytek Biosciences' Q1 2025: Unpacking Tariff Impacts, Growth Strategies, and Replacement Cycle Opportunities
May 19,2025 12:10
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.01
Actual EPS-0.04
Estimate Revenue46.35M
Actual Revenue45.60M
Cytek's 2025 Q2 Earnings: Navigating Contradictions in Sales, Margins, and Market Growth
Aug 07,2025 04:36
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CTKB has released its 2025 Q3 earnings. EPS was reported at -0.04, versus the expected 0.01, missing expectations. The chart below visualizes how CTKB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CTKB has released its 2025 Q3 earnings report, with revenue of 52.29M, reflecting a YoY change of 1.54%, and net profit of -5.48M, showing a YoY change of -682.15%. The Sankey diagram below clearly presents CTKB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
